2020-07-06: Congratulations Carlos Fernandez and all our collaborators for the impressive work leading to "Defining an Optimal Dual-Targeted CAR T Cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA-Escape Driven Relapse in Multiple Myeloma" in Blood Cancer Discovery !! Carlos' work elucidates important lessons for how dual-targeted CAR design impacts function in settings of varying antigen expression and uncovers some interesting biology underpinning the differences. Link here.
2020-06-01: Congrats to Sham Mailankody and the Orva-Cel (formerly JCARH125) team for an outstanding oral presentation reporting an exciting update on clinical outcomes with BCMA-targeted CAR T cells stemming from our lab work.
2020-06-01: The SITC consensus statement on immunotherapy for myeloma accepted for publication (Dr. Smith co-author). Will provide guidelines for on all aspects of treatment with and management of toxicities of immunotherapy for MM (in press).
2020-05-11: Dr. Smith presents at the American Society of Gene and Cell Therapy Annual Meeting (virtual) on BCMA targeted CAR T cells and beyond.
2019-12-09: Congrats to Andrew Cowan (Fred Hutch) on the oral presentation of his clinical investigation "Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma" using a vector stemming from the work of our group
2019-12-08: Congrats to Carlos Fernandez on an outstanding oral presentation of our pre-clinical work: Optimal dual-targeted CAR construct simultaneously targeting BCMA and GPRC5D prevents BCMA-escape driven relapse in MM which was additionally featured in the Best of ASH CAR T cells; and the MM immunotherapy educational sessions